公开(公告)号：KR1020130083267A

公开(公告)日：2013-07-22

申请号：KR1020120003950

申请日：2012-01-12

Applicant: 전남대학교산학협력단

Inventor： 조덕 ,  장윤영 ,  김상기 ,  이제중

IPC: C12Q1/66 ,  C12Q1/02 ,  C12N5/0783 ,  C12N15/85

CPC classification number: C12Q1/66 ,  C12N5/0081 ,  C12N5/0646 ,  C12N15/85 ,  G01N33/5005

Abstract: PURPOSE: A method for measuring the activity of natural killer cells (NK cells) is provided to test with the same accuracy as a standard method (^51Cr release method) using a luciferase expression cell line without radioactive isotopes. CONSTITUTION: A method for measuring the activity of NK cells comprises the steps of: mixing a measuring sample containing the NK cells and a target sample containing a luciferase expression cell line; adding luciferin to the mixture of the measuring sample and the target sample; and measuring light generated while luciferin turns into oxyluciferin by the action of luciferase. The luciferase expression cell line is prepared by inserting luciferase genes into one cell line among K562, ES-8, HL-60, Daudi, and ARH77.

Abstract translation: 目的：提供一种测量自然杀伤细胞（NK细胞）活性的方法，使用不含放射性同位素的荧光素酶表达细胞系，以与标准方法（^ 51Cr释放方法）相同的精确度进行测试。 构成：测量NK细胞活性的方法包括以下步骤：将含有NK细胞的测定样品和含有荧光素酶表达细胞系的靶标样品混合; 将荧光素加入到测量样品和目标样品的混合物中; 并且通过荧光素酶的作用测量荧光素变成氧化荧光素时产生的光。 通过将荧光素酶基因插入到K562，ES-8，HL-60，Daudi和ARH77中的一个细胞系中来制备荧光素酶表达细胞系。

公开(公告)号：KR101756073B1

公开(公告)日：2017-07-11

申请号：KR1020150140390

申请日：2015-10-06

Applicant: 전남대학교산학협력단 ,  주식회사 박셀바이오

Inventor： 이제중 ,  최누리 ,  이현주 ,  정성훈

IPC: A61K38/16 ,  C12N5/09 ,  C12N5/0784 ,  C12Q1/68

CPC classification number: A61K38/16 ,  C12Q1/68

Abstract: 본발명은암-고환항원을포함하는한국난치성다발골수종암 면역치료또는예방용조성물에관한것으로, 상기항원을탑재한수지상세포및 이로부터유도되는암-고환항원특이적세포독성 T 림프구세포를유효성분으로포함하는다발골수종예방또는치료용세포면역치료제조성물을이용함으로써암 면역치료에있어강력한종양특이적세포독성면역반응을유도하는동시에안전하고부작용이없는암 치료용백신으로유용하게활용할수 있을것으로기대된다.

公开(公告)号：KR101083404B1

公开(公告)日：2011-11-14

申请号：KR1020110036726

申请日：2011-04-20

Applicant: 전남대학교산학협력단

Inventor： 이제중 ,  홍철이 ,  김미현

IPC: C12N5/0784 ,  C12N5/02 ,  C07K14/52 ,  A61K38/19

Abstract: PURPOSE: A method for enhancing dendritic cell migration and ability of killing cytotoxic T cells is provided to improve migration of cendritic cells into a secondary lymphoid organ. CONSTITUTION: A composition for enhancing migration of dendritic cells contains chemokines including CCL21, CCL19, or mixture thereof. An active ingredient relates to migration of a secondary lymphoid organ by 10-250 ng/mL. A method for enhancing cell killing ability of cytotoxic T cells comprises a step of adding chemokine to monocytes during differenetion of immature dendritic cells into dendritic cells and culturing the dendritic cells.

Abstract translation: 目的：提供增强树突细胞迁移和杀死细胞毒性T细胞的能力的方法，以改善树突状细胞向次级淋巴器官的迁移。 构成：用于增强树突细胞迁移的组合物含有趋化因子，包括CCL21，CCL19或其混合物。 活性成分涉及二级淋巴器官的迁移10-250ng / mL。 增强细胞毒性T细胞杀伤细胞能力的方法包括在将未成熟树突细胞分化成树突状细胞并培养树突细胞的过程中向单核细胞中加入趋化因子。

公开(公告)号：KR100997753B1

公开(公告)日：2010-12-02

申请号：KR1020100013088

申请日：2010-02-12

Applicant: 전남대학교산학협력단

Inventor： 이제중 ,  홍철이 ,  이준행 ,  이현주

IPC: C12N5/0784 ,  C12N5/02 ,  C07K14/525 ,  C07K14/555

CPC classification number: C12N5/0639 ,  C07K14/525 ,  C07K14/555 ,  C12N1/38 ,  C12N2501/24 ,  C12N2501/25 ,  C12N2501/998

Abstract: PURPOSE: A composition for inducing maturation of dendritic cells is provided to use as a therapeutic agent for tumor. CONSTITUTION: A composition for inducing maturation of dendritic cells contains bacteria flagellin, TNF-alpha, and interferone as active ingredients. A method for inducing maturation of immature dendritic cells comprises: a step of differentiating monocytes isolated from blood to immature dendritic cells; and a step of treating with bacteria flagellin, TNF-alpha and interferone to the immature dendtritic cells.

Abstract translation: 目的：提供一种用于诱导树突细胞成熟的组合物，用作肿瘤的治疗剂。 构成：用于诱导树突状细胞成熟的组合物含有细菌鞭毛蛋白，TNF-α和干扰素作为活性成分。 用于诱导未成熟树突状细胞成熟的方法包括：将从血液中分离的单核细胞分化成未成熟树突状细胞的步骤; 以及用细菌鞭毛蛋白，TNF-α和干扰素处理未成熟树突状细胞的步骤。

公开(公告)号：KR100982186B1

公开(公告)日：2010-09-14

申请号：KR1020100005405

申请日：2010-01-21

Applicant: 전남대학교산학협력단

Inventor： 이제중 ,  이현주 ,  홍철이

IPC: A61K38/16 ,  A61K39/235 ,  A61P35/00

CPC classification number: A61K39/0011 ,  A61K2039/5154 ,  A61K38/1764 ,  A61K39/235 ,  C07K14/4748 ,  Y10S514/885

Abstract: PURPOSE: A novel tumor antigen protein AGR2 and tumor antigenic peptide thereof are provided to induce tumor-specific cytotoxicity immune response. CONSTITUTION: A cellular immunotherapeutic agent composition for preventing or treating colorectal cancer comprises dendritic cells having human AGR2(anterior gradient-2) tumor antigenic peptide with an amino sequences of sequence number 6 or 12 or AGR2-specific cytotoxic T lymphocytes which is secreted from the dendritic cells as active ingredients. A method for manufacturing cellular immunotherapeutic agent composition for treating or preventing colorectal cancer comprises: a step of loading the human AGR2 tumor antigenic peptide; and a step of co-culturing the loaded dendritic cells and T lymphocytes.

Abstract translation: 目的：提供一种新的肿瘤抗原蛋白AGR2及其肿瘤抗原肽，以诱导肿瘤特异性细胞毒性免疫应答。 构成：用于预防或治疗结肠直肠癌的细胞免疫治疗剂组合物包含具有序列号6或12的氨基酸序列的人AGR2（前向梯度-2）肿瘤抗原肽或AGR2特异性细胞毒性T淋巴细胞的树突状细胞，其由 树突细胞作为活性成分。 用于制备用于治疗或预防结肠直肠癌的细胞免疫治疗剂组合物的方法包括：载入人AGR2肿瘤抗原肽的步骤; 以及共培养负载的树突状细胞和T淋巴细胞的步骤。

公开(公告)号：KR1020170040996A

公开(公告)日：2017-04-14

申请号：KR1020150140390

申请日：2015-10-06

Applicant: 전남대학교산학협력단 ,  주식회사 박셀바이오

Inventor： 이제중 ,  최누리 ,  이현주 ,  정성훈

IPC: A61K38/16 ,  C12N5/09 ,  C12N5/0784 ,  C12Q1/68

CPC classification number: A61K38/16 ,  C12Q1/68

Abstract: 본발명은암-고환항원을포함하는한국난치성다발골수종암 면역치료또는예방용조성물에관한것으로, 상기항원을탑재한수지상세포및 이로부터유도되는암-고환항원특이적세포독성 T 림프구세포를유효성분으로포함하는다발골수종예방또는치료용세포면역치료제조성물을이용함으로써암 면역치료에있어강력한종양특이적세포독성면역반응을유도하는동시에안전하고부작용이없는암 치료용백신으로유용하게활용할수 있을것으로기대된다.

Abstract translation: 本发明的癌症韩国难治束骨髓jongam免疫治疗或预防性组合物，包括睾丸抗原，癌症衍生自树突细胞，并且其配备有可用于细胞毒性T淋巴细胞细胞睾丸抗原的抗原特异性细胞 使用多发性骨髓瘤的预防或治疗的细胞免疫治疗剂组合物，包括作为分量通过，以便能够无需在同一时间利用，因为它强的肿瘤特异性的细胞毒性有用诱导免疫应答的癌症疫苗的治疗在癌症免疫疗法的安全和副作用 预计。

公开(公告)号：KR101117186B1

公开(公告)日：2012-03-07

申请号：KR1020110061540

申请日：2011-06-24

Applicant: 전남대학교산학협력단

Inventor： 홍철이 ,  이제중 ,  김미현

IPC: C12N5/0784 ,  C12N5/02 ,  C07K14/52

Abstract: PURPOSE: A method for enhancing cytotoxicity of cytotoxic T cells is provided to enhance mobility of dendritic cells to a second lymph organ and to induce maturation of novel dendritic cells. CONSTITUTION: A method for enhancing cytotoxicity of cytotoxic T cells comrises: a step of differentiating monocytes isolated from blood into immature dendritic cells; a step of treating antiviral cytokines, TLR activator, or mixture thereof to the immature dendritic cells to culture the immature dendritic cells; a step of treating a composition for enhancing mobility of dendritic cells to the immature dendritic cells to maturing the immature dendritic cells; and a step of adding IP-10(interferon-gamma inducible protein-10) to the matured dendritic cells.

Abstract translation: 目的：提供增强细胞毒性T细胞的细胞毒性的方法，以增强树突状细胞对第二淋巴管的迁移，并诱导新型树突状细胞的成熟。 构成：增强细胞毒性T细胞的细胞毒性的方法：将从血液中分离的单核细胞分化成未成熟树突状细胞的步骤; 将抗病毒细胞因子，TLR活化剂或其混合物处理至未成熟树突细胞以培养未成熟树突状细胞的步骤; 处理组合物以增强树突状细胞对未成熟树突细胞的迁移率以成熟未成熟树突状细胞的步骤; 以及向成熟树突状细胞中加入IP-10（干扰素-γ诱导型蛋白-10）的步骤。

公开(公告)号：KR100954887B1

公开(公告)日：2010-04-28

申请号：KR1020090051422

申请日：2009-06-10

Applicant: 전남대학교산학협력단

Inventor： 이제중 ,  마사오다케이 ,  우메야마아케미 ,  김규식

IPC: C12N5/0784

CPC classification number: C12N5/064

Abstract: PURPOSE: Matured dendritic cells by uncarinic acid C are provided to enhance the differentiation of nave T cells to Th1 cells and to induce specific reaction. CONSTITUTION: A mutured dendritic cell is obtained by adding uncarinic acid C to immature dendritic cells and culturing. A composition for immunotherapy contains dendritic cells, T cells differentiated therefrom, or cytokine produced thereby. The uncarinic acid C is isolated from Uncaria rhynchophylla. A method for producing the matured dendritic cells comprises: a step of adding uncarinic acid C to immature dendritic cells by intravenous or hypodermic infection, and a step of culturing the dendritic cells.

Abstract translation: 目的：提供通过脱羧酸C的成熟树突状细胞，以增强纳瓦T细胞与Th1细胞的分化并诱导特异性反应。 构成：通过向未成熟的树突状细胞中加入非卡洛芬酸C并进行培养获得了一种突变的树突状细胞。 用于免疫治疗的组合物包含树突状细胞，从其分化的T细胞或由此产生的细胞因子。 脱羧酸C分离自钩藤草（Uncaria rhynchophylla）。 一种生产成熟树突状细胞的方法包括：通过静脉内或皮下感染向未成熟树突细胞中添加非卡里酸C的步骤和培养树突状细胞的步骤。